These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32503882)

  • 61. Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
    Bissada JE; Truong V; Abouda AA; Wines KJ; Crouch RD; Jackson KD
    Drug Metab Dispos; 2019 Nov; 47(11):1257-1269. PubMed ID: 31492693
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.
    van Dyk M; Miners JO; Marshall JC; Wood LS; Hopkins A; Sorich MJ; Rowland A
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1211-1218. PubMed ID: 31123759
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cytochrome P450 1A2 Messenger RNA is a More Reliable Marker than Cytochrome P450 1A2 Activity, Phenacetin O-Deethylation, for Assessment of Induction Potential of Drug-Metabolizing Enzymes Using HepaRG Cells.
    Ogasawara A; Kato N; Torimoto N; Aohara F; Ohashi R; Yamada Y; Taniguchi H
    Drug Metab Lett; 2018; 12(1):14-23. PubMed ID: 29357810
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
    Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
    Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.
    Elens L; Nieuweboer AJ; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; van Gelder T; Mathijssen RH; van Schaik RH
    Pharmacogenet Genomics; 2013 Mar; 23(3):148-55. PubMed ID: 23324807
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines.
    Vrzal R; Kubesova K; Pavek P; Dvorak Z
    Toxicol Lett; 2010 Mar; 193(2):183-8. PubMed ID: 20080160
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
    Zhang ZY; King BM; Pelletier RD; Wong YN
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):707-16. PubMed ID: 18431572
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys.
    Ohtsuka T; Yoshikawa T; Kozakai K; Tsuneto Y; Uno Y; Utoh M; Yamazaki H; Kume T
    Drug Metab Dispos; 2010 Oct; 38(10):1806-13. PubMed ID: 20584745
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
    Adeloye T; Sahgal O; Puri A; Warrington S; Endo T; Dennison J; Johnston A
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):844-859. PubMed ID: 30044899
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
    Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
    Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
    Zhou SF
    Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics.
    Gashaw I; Kirchheiner J; Goldammer M; Bauer S; Seidemann J; Zoller K; Mrozikiewicz PM; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2003 Nov; 74(5):448-57. PubMed ID: 14586385
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
    Tahara H; Watanabe M; Hasegawa M
    Biopharm Drug Dispos; 2019 Feb; 40(2):81-93. PubMed ID: 30724384
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
    Mao J; Johnson TR; Shen Z; Yamazaki S
    Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A useful model capable of predicting the clearance of cytochrome 3A4 (CYP3A4) substrates in humans: validity of CYP3A4 transgenic mice lacking their own Cyp3a enzymes.
    Mitsui T; Nemoto T; Miyake T; Nagao S; Ogawa K; Kato M; Ishigai M; Yamada H
    Drug Metab Dispos; 2014 Sep; 42(9):1540-7. PubMed ID: 25005602
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
    Ou Y; Xu Y; Gore L; Harvey RD; Mita A; Papadopoulos KP; Wang Z; Cutler RE; Pinchasik DE; Tsimberidou AM
    Br J Clin Pharmacol; 2019 Mar; 85(3):530-539. PubMed ID: 30428505
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes.
    Wu YL; Xue YR; Guo ZT; Chen ZD; Ge XY; Zhong DF; Diao XX
    Acta Pharmacol Sin; 2022 Mar; 43(3):747-756. PubMed ID: 34035488
    [TBL] [Abstract][Full Text] [Related]  

  • 80. VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
    Zetterberg C; Maltais F; Laitinen L; Liao S; Tsao H; Chakilam A; Hariparsad N
    Drug Metab Dispos; 2016 Aug; 44(8):1286-95. PubMed ID: 27298338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.